Soon, new compounds to sensitize cancerous tumors to therapy
August 6th, 2009 - 2:28 pm ICT by ANI ( Leave a comment )Washington, Aug 6 (ANI): Melanoma, an aggressive form of skin cancer, and glioblastoma multiforme brain cancer respond very poorly to chemotherapy and radiation. Now, scientists at The University of Arizona are attempting to find natural, biologically active compounds that will sensitise the cancerous tumours to therapy without damaging normal tissue.
By using the compounds in conjunction with conventional treatment, the researchers hope patient survival rates will ultimately increase.
Dacarbazine, the standard chemotherapeutic drug for melanoma for decades, has been ineffective when used alone.
To improve its performance, Randy Burd, assistant professor of nutritional sciences and member of the UA’s BIO5 Institute, has been testing the drug and its new analog Temozolomide in combination with various bioactive compounds to gain greater response rates on melanoma tumours in cell cultures.
“After working with COX-2 inhibitors - which had complications - we started looking at quinones, which occur in nature as pigments, vitamin biochemical backbones and plant compounds, and then we analyzed the enzymes involved in their activation,” Burd said.
Quercetin, a polyphenol found in apples, onions, green tea and other plant-based foods, is a quinone that has shown an interesting effect on melanoma tumours.
In low concentrations, quercetin behaves as an antioxidant, yet at high concentrations it becomes a cell-damaging pro-oxidant.
Burd’s team is exploiting the pro-oxidant attribute of quercetin, using tyrosinase, which is the highly expressed enzyme responsible for the pigment formation in human skin cells that grow out of control in melanoma.
“The quercetin is similar to precursors of melanin. The tyrosinase actually recognizes and activates quercetin to a pro-oxidant rather than an antioxidant,” Burd said.
When tested together in melanoma tumour cell cultures, the result is tumour cell death. The melanoma enzyme is tricked into activating so much quercetin that it turns around and sensitizes the melanoma cells to the chemotherapy drug, and they die.
According to Burd, Quercetin is an example of a biological response modifier, which is a drug or a compound that changes the function of tumour cells so they will be more responsive to chemotherapy or radiation.
In the case of glioblastoma multiforme brain cancer, the focus is on finding and screening quinones that could be used in the brain to reverse the radiation-resistance of tumours, and then using those compounds in conjunction with radiation treatment. (ANI)
- New procedure busts deadly brain tumour cells - Feb 06, 2012
- Molecule able to fight brain cancer found - Apr 22, 2011
- Experimental lung cancer drug may help treat brain, prostate cancer - Jan 04, 2010
- Arthritis drug could help treat skin cancer - Mar 24, 2011
- Bad cholesterol feeds brain tumours - Sep 16, 2011
- Herbal remedy beats brain cancer - Jul 13, 2011
- 'Designer protein' opens new door in cancer research - Aug 04, 2010
- Brain tumour's 'grow-or-go' switch found - Mar 12, 2010
- Scientists identify four anti-cancer compounds - Nov 30, 2011
- Cottonseed-based drug may help treat severe brain cancer - May 29, 2009
- Skin cancer pill shrinks tumour in 80 percent cases - Aug 26, 2010
- Genes that drive aggressive brain cancers identified - Dec 24, 2009
- Zebrafish model reveals skin cancer-promoting gene - Mar 24, 2011
- Mechanism that helps brain cancer evade immune system attack discovered - Jan 16, 2010
- Protein that could treat aggressive brain tumour identified - Dec 23, 2009
Tags: bioactive compounds, brain cancer, burd, cancerous tumors, cancerous tumours, cell cultures, chemotherapeutic drug, conventional treatment, cox 2 inhibitors, dacarbazine, human skin cells, patient survival rates, plant compounds, polyphenol, pro oxidant, quinone, skin cancer, temozolomide, tumour cell, tyrosinase